Top 5 Bank Stocks To Watch Right Now

15 Most Overlooked Tax Deductions: 2017

For Fiduciary Rule, Morningstar Sees Up to $150M in Annual Class Action Settlements

Top 10 Cities for Millennial Homebuyers

Wells Fargo & Co. said credit-card applications dropped 55 percent in February from a year earlier, the biggest decline since a scandal involving fake accounts erupted in September.

Retail customers opened 43 percent fewer checking accounts in February, marking the sixth straight month of declines since regulators fined the bank over the creation of unauthorized accounts.

Copyright 2017 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

The service, to be called Intuitive Investor, aims to bring in new, younger clients to its wealth management unit.

You are signed up!

ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Resources 5 Steps to Eradicate Text Messaging Risk

In this White Paper, we share five steps to help you build a risk management program that enables the benefits of text messaging while protecting…

Top 5 Bank Stocks To Watch Right Now: Boardwalk Pipeline Partners L.P.(BWP)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested mid cap natural gas pipeline stock Boardwalk Pipeline Partners, LP (NYSE: BWP) as a bullish/long trade:

Top 5 Bank Stocks To Watch Right Now: Home Federal Bancorp Inc.(HOME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of At Home Group Inc (NYSE: HOME) were down 10 percent to $23.19. At Home Group reported Q2 adjusted earnings of $0.18 per share on revenue of $232.1 million.

  • [By Sofia Horta e Costa]

    Sanofi fell 2.6 percent after withdrawing a U.S. application for a diabetes drug. Cie. Financiere Richemont (CFR) SA dropped 2.3 percent as revenue missed analysts estimates. Vivendi SA advanced 2.7 percent after saying it will begin a formal study to separate its French phone unit from its media businesses. Home Retail Group Plc (HOME) surged 5.4 percent to a two-year high as sales exceeded projections.

Top 5 Bank Stocks To Watch Right Now: Helix Energy Solutions Group, Inc.(HLX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Energy shares climbed by 1.10 percent in trading on Tuesday. Meanwhile, top gainers in the sector included Helix Energy Solutions Group Inc (NYSE: HLX), and SunPower Corporation (NASDAQ: SPWR).

  • [By Lisa Levin]

    On Friday, energy shares gained by 2.70 percent. Meanwhile, top gainers in the sector included Denbury Resources Inc. (NYSE: DNR), up 14 percent, and Helix Energy Solutions Group Inc (NYSE: HLX), up 16 percent.

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Lisa Levin]

    In trading on Wednesday, energy shares fell by 1.01 percent. Meanwhile, top losers in the sector included Helix Energy Solutions Group Inc (NYSE: HLX), down 11 percent, and CARBO Ceramics Inc. (NYSE: CRR), down 10 percent.

  • [By Lisa Levin]

    Energy sector was the top gainer in the US market on Monday. Top gainers in the sector included Helix Energy Solutions Group Inc (NYSE: HLX), SM Energy Co (NYSE: SM), and Ecopetrol SA (ADR) (NYSE: EC).

Top 5 Bank Stocks To Watch Right Now: Liberty Interactive Corporation(QVCA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    QVC (QVCA) was upgraded to buy from neutral at Bank of America/Merrill Lynch. $25 price target. The company can turn its sales around and deserves a higher multiple, analysts said. 

Top 5 Bank Stocks To Watch Right Now: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Todd Campbell]

    The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

    Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

Leave a Reply

Your email address will not be published. Required fields are marked *